dr. camidge on crizotinib as a ros1 inhibitor in nsclc
Published 11 years ago • 242 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
2:29
dr. ross camidge discusses crizotinib in ros1 rearranged nsclc
-
0:56
crizotinib for first line treatment of alk or ros1 rearrangements
-
2:03
dr. levy on the efficacy of crizotinib versus entrectinib in ros1 lung cancer
-
4:55
ros1-rearranged nsclc
-
1:51
dr. camidge discusses treatment of patients with alk nsclc
-
1:58
dr. camidge on mechanisms of resistance to tkis in nsclc
-
3:15
ros1 rearrangements in mnsclc
-
1:27
dr. ou on the use of crizotinib in patients with ros1-rearranged nsclc
-
1:00
dr. camidge on phase i study with azd9291 in nsclc
-
2:12
dr. drilon on entrectinib in patients with ros1-positive nsclc
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
1:22
dr. crinò on crizotinib in alk nsclc
-
1:51
dr. riess on ros1 fusions in lung cancer
-
2:45
crizotinib treatment in lung adenocarcinoma patient with ros1 fusion – video abstract id 136297
-
1:53
ros-1 rearrangements: what are they?
-
2:52
q&a: cabozantinib for ros1 after progression on crizotinib - targeted therapies in lung cancer 2023
-
12:46
gracecast-086_lung-cancer_q&a with drs. solomon and camidge on alk inhibition for advanced nsclc
-
6:04
case study: progression on alk inhibitors in nsclc
-
1:00
dr. camidge discusses unmet needs in alk lung cancer